XTLB – X.T.L. Biopharmaceuticals Ltd. ADR

Float Short %

0.14

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.67

Target Price

Analyst Recom

Performance Q

-52.85

Relative Volume

0.06

Beta

1.17

Ticker: XTLB

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	XTLB	0.8795	N/A	N/A	0
2025-12-10	XTLB	0.8101	N/A	N/A	0
2025-12-11	XTLB	0.82	N/A	N/A	0
2025-12-12	XTLB	0.8153	N/A	N/A	0
2025-12-15	XTLB	0.8325	N/A	N/A	0
2025-12-16	XTLB	0.78	N/A	N/A	0
2025-12-17	XTLB	0.7849	N/A	N/A	0
2025-12-18	XTLB	0.81	N/A	N/A	0
2025-12-19	XTLB	0.815	N/A	N/A	0
2025-12-22	XTLB	0.7861	N/A	N/A	0
2025-12-23	XTLB	0.78	N/A	N/A	0
2025-12-26	XTLB	0.7148	N/A	N/A	0
2025-12-29	XTLB	0.6666	N/A	N/A	0
2025-12-30	XTLB	0.6601	N/A	N/A	0
2025-12-31	XTLB	0.5744	N/A	N/A	0
2026-01-02	XTLB	0.59	N/A	N/A	0
2026-01-05	XTLB	0.62	N/A	N/A	0
2026-01-06	XTLB	0.6803	N/A	N/A	0
2026-01-07	XTLB	0.688	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	XTLB	0.88	-	-	-
2025-12-10	XTLB	0.80	-	-	-
2025-12-11	XTLB	0.84	-	-	-
2025-12-12	XTLB	0.83	-	-	-
2025-12-15	XTLB	0.81	-	-	-
2025-12-16	XTLB	0.81	-	-	-
2025-12-17	XTLB	0.78	-	-	-
2025-12-18	XTLB	0.86	-	-	-
2025-12-19	XTLB	0.85	-	-	-
2025-12-22	XTLB	0.80	-	-	-
2025-12-23	XTLB	0.79	-	-	-
2025-12-26	XTLB	0.71	-	-	-
2025-12-29	XTLB	0.67	-	-	-
2025-12-30	XTLB	0.66	-	-	-
2025-12-31	XTLB	0.57	-	-	-
2026-01-02	XTLB	0.58	-	-	-
2026-01-05	XTLB	0.63	-	-	-
2026-01-06	XTLB	0.69	-	-	-
2026-01-07	XTLB	0.67	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	XTLB	0.00	-25.26	0.14
2025-12-10	XTLB	0.00	-25.26	0.03
2025-12-11	XTLB	0.00	-25.26	0.03
2025-12-12	XTLB	0.00	-25.26	0.03
2025-12-15	XTLB	0.00	-25.22	0.03
2025-12-16	XTLB	0.00	-25.22	0.03
2025-12-17	XTLB	0.00	-25.22	0.03
2025-12-18	XTLB	0.00	-25.22	0.03
2025-12-19	XTLB	0.00	-25.22	0.03
2025-12-22	XTLB	0.00	-24.99	0.03
2025-12-23	XTLB	0.00	-24.99	0.03
2025-12-26	XTLB	0.00	-24.99	0
2025-12-29	XTLB	0.00	-22.10	0.14
2025-12-30	XTLB	0.00	-22.10	0.14
2025-12-31	XTLB	0.00	-22.10	0.14
2026-01-02	XTLB	0.00	-22.10	0.14
2026-01-05	XTLB	0.00	-21.37	0.14
2026-01-06	XTLB	0.00	-21.37	0.14
2026-01-07	XTLB	0.00	-21.37	0.14
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-21.37

Beta

1.17

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

89.9

Max Drawdown 5-Year %

-88.8

Target Price

P/E

Forward P/E

PEG

P/S

13.88

P/B

1.07

P/Free Cash Flow

EPS

-0.11

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-227.01

Relative Volume

0.06

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

XTL Biopharmaceuticals Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 10

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

stock quote shares XTLB – X.T.L. Biopharmaceuticals Ltd. ADR Stock Price stock today

news today XTLB – X.T.L. Biopharmaceuticals Ltd. ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch XTLB – X.T.L. Biopharmaceuticals Ltd. ADR yahoo finance google finance

stock history XTLB – X.T.L. Biopharmaceuticals Ltd. ADR invest stock market

stock prices XTLB premarket after hours

ticker XTLB fair value insiders trading

XNCR – Xencor Inc

Float Short %

14.17

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

-4.03

EPS Last/This Y

1.75

EPS This/Next Y

-0.84

Price

14.93

Target Price

28.31

Analyst Recom

1.21

Performance Q

24.27

Relative Volume

1.57

Beta

0.98

Ticker: XNCR

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	XNCR	16.81	0.40	8.75	1276
2025-12-10	XNCR	17.16	0.40	8.75	1276
2025-12-11	XNCR	17.04	0.43	0.07	1315
2025-12-12	XNCR	16.51	0.43	0.00	1320
2025-12-15	XNCR	16.79	0.43	0.00	1321
2025-12-16	XNCR	16.53	0.43	0.00	1321
2025-12-17	XNCR	15.8	0.43	0.00	1321
2025-12-18	XNCR	15.7	0.43	0.00	1322
2025-12-19	XNCR	15.53	0.43	1.00	1324
2025-12-22	XNCR	15.96	0.04	20.00	955
2025-12-23	XNCR	15.47	0.08	999.99	993
2025-12-26	XNCR	15.23	0.17	0.00	1073
2025-12-29	XNCR	15.16	0.17	0.00	1073
2025-12-30	XNCR	15.02	0.17	999.99	1067
2025-12-31	XNCR	15.3	0.17	999.99	1067
2026-01-02	XNCR	14.91	0.17	999.99	1067
2026-01-05	XNCR	14.27	0.18	0.00	1078
2026-01-06	XNCR	14.06	0.18	0.00	1078
2026-01-07	XNCR	14.94	0.18	1.50	1080
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	XNCR	16.81	5.3	-	-1.79
2025-12-10	XNCR	17.15	5.3	-	-1.79
2025-12-11	XNCR	17.04	5.3	-	-1.79
2025-12-12	XNCR	16.53	5.3	-	-1.79
2025-12-15	XNCR	16.79	5.7	-	-1.79
2025-12-16	XNCR	16.79	5.7	-	-1.79
2025-12-17	XNCR	15.80	5.7	-	-1.79
2025-12-18	XNCR	15.69	5.7	-	-1.79
2025-12-19	XNCR	15.53	5.7	-	-1.83
2025-12-22	XNCR	16.01	5.7	-	-1.83
2025-12-23	XNCR	15.44	5.7	-	-1.83
2025-12-26	XNCR	15.22	5.7	-	-1.83
2025-12-29	XNCR	15.18	5.7	-	-1.83
2025-12-30	XNCR	15.02	5.7	-	-1.83
2025-12-31	XNCR	15.31	5.7	-	-1.83
2026-01-02	XNCR	14.91	5.7	-	-1.83
2026-01-05	XNCR	14.27	5.7	-	-1.83
2026-01-06	XNCR	14.06	5.7	-	-1.83
2026-01-07	XNCR	14.93	5.7	-	-1.83
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	XNCR	-0.33	-3.59	12.53
2025-12-10	XNCR	-0.33	-3.59	13.25
2025-12-11	XNCR	-0.33	-3.59	13.25
2025-12-12	XNCR	-0.33	-3.59	13.25
2025-12-15	XNCR	-0.33	-3.60	13.25
2025-12-16	XNCR	-0.33	-3.60	13.25
2025-12-17	XNCR	0.00	-3.60	13.25
2025-12-18	XNCR	0.00	-3.60	13.25
2025-12-19	XNCR	0.00	-3.60	13.25
2025-12-22	XNCR	0.00	-3.60	13.25
2025-12-23	XNCR	0.00	-3.60	13.25
2025-12-26	XNCR	-4.16	-3.60	14.17
2025-12-29	XNCR	-4.16	-3.60	14.17
2025-12-30	XNCR	-4.14	-3.60	14.17
2025-12-31	XNCR	-4.14	-3.60	14.17
2026-01-02	XNCR	-4.14	-3.60	14.17
2026-01-05	XNCR	-4.14	-3.60	14.17
2026-01-06	XNCR	-4.14	-3.60	14.17
2026-01-07	XNCR	-4.14	-3.60	14.17
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

3.39

Avg. EPS Est. Current Quarter

-0.58

Avg. EPS Est. Next Quarter

-0.64

Insider Transactions

-4.14

Institutional Transactions

-3.6

Beta

0.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

74.4

Max Drawdown 5-Year %

-87

Target Price

28.31

P/E

Forward P/E

PEG

P/S

7.11

P/B

1.71

P/Free Cash Flow

EPS

-1.78

Average EPS Est. Cur. Y

-1.83

EPS Next Y. (Est.)

-2.67

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-87.14

Relative Volume

1.57

Return on Equity vs Sector %

-48

Return on Equity vs Industry %

-32.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.06

EBIT Estimation

Xencor, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 250

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

stock quote shares XNCR – Xencor Inc Stock Price stock today

news today XNCR – Xencor Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch XNCR – Xencor Inc yahoo finance google finance

stock history XNCR – Xencor Inc invest stock market

stock prices XNCR premarket after hours

ticker XNCR fair value insiders trading

TARS – Tarsus Pharmaceuticals Inc

Float Short %

17.39

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.23

EPS Last/This Y

1.66

EPS This/Next Y

2.75

Price

78.03

Target Price

87.5

Analyst Recom

1.3

Performance Q

14.12

Relative Volume

1.31

Beta

0.57

Ticker: TARS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	TARS	79.49	0.03	0.00	2560
2025-12-10	TARS	81.19	0.03	0.00	2582
2025-12-11	TARS	81.74	0.03	0.00	2590
2025-12-12	TARS	81.35	0.03	0.00	2588
2025-12-15	TARS	80.49	0.03	0.00	2594
2025-12-16	TARS	78.29	0.03	0.04	2596
2025-12-17	TARS	77.81	0.04	0.65	2615
2025-12-18	TARS	77.45	0.33	0.02	5994
2025-12-19	TARS	81.34	0.34	0.02	5928
2025-12-22	TARS	81.44	0.37	0.04	5330
2025-12-23	TARS	82.25	0.37	0.04	5285
2025-12-26	TARS	81.73	0.39	1.08	5317
2025-12-29	TARS	82.02	0.39	3.00	5329
2025-12-30	TARS	82.36	0.40	0.38	5343
2025-12-31	TARS	81.84	0.40	0.43	5338
2026-01-02	TARS	80.7	0.40	0.42	5346
2026-01-05	TARS	79.78	0.40	0.44	5382
2026-01-06	TARS	79.16	0.41	0.33	5393
2026-01-07	TARS	77.72	0.41	1.44	5391
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	TARS	79.55	98.7	-	-1.42
2025-12-10	TARS	81.24	99.4	-	-1.41
2025-12-11	TARS	81.76	99.4	-	-1.41
2025-12-12	TARS	81.39	99.4	-	-1.41
2025-12-15	TARS	80.48	99.4	-	-1.41
2025-12-16	TARS	80.48	99.4	-	-1.41
2025-12-17	TARS	77.80	99.4	-	-1.41
2025-12-18	TARS	77.46	99.4	-	-1.41
2025-12-19	TARS	81.39	99.4	-	-1.41
2025-12-22	TARS	81.60	99.4	-	-1.41
2025-12-23	TARS	82.18	99.4	-	-1.41
2025-12-26	TARS	81.75	99.4	-	-1.41
2025-12-29	TARS	81.97	99.4	-	-1.41
2025-12-30	TARS	82.35	99.4	-	-1.41
2025-12-31	TARS	81.96	99.4	-	-1.41
2026-01-02	TARS	80.60	99.4	-	-1.41
2026-01-05	TARS	79.81	99.4	-	-1.41
2026-01-06	TARS	79.80	99.4	-	-1.41
2026-01-07	TARS	78.03	99.4	-	-1.41
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	TARS	-2.09	-4.23	18.33
2025-12-10	TARS	-2.09	-4.23	18.20
2025-12-11	TARS	-2.09	-4.23	18.20
2025-12-12	TARS	-1.58	-4.23	18.20
2025-12-15	TARS	-1.58	-4.23	18.19
2025-12-16	TARS	-1.59	-4.23	18.19
2025-12-17	TARS	-2.28	-4.23	18.19
2025-12-18	TARS	-2.10	-4.23	18.19
2025-12-19	TARS	-2.10	-4.23	18.19
2025-12-22	TARS	-2.10	-4.24	18.18
2025-12-23	TARS	-2.12	-4.24	18.18
2025-12-26	TARS	-2.12	-4.24	17.39
2025-12-29	TARS	-2.12	-4.19	17.39
2025-12-30	TARS	-2.12	-4.19	17.39
2025-12-31	TARS	-2.29	-4.19	17.39
2026-01-02	TARS	-2.29	-4.19	17.39
2026-01-05	TARS	-2.29	-3.99	17.39
2026-01-06	TARS	-2.75	-3.99	17.39
2026-01-07	TARS	-2.75	-3.99	17.39
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.3

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

-2.75

Institutional Transactions

-3.99

Beta

0.57

Average Sales Estimate Current Quarter

143

Average Sales Estimate Next Quarter

148

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

8.5

Max Drawdown 5-Year %

-76.6

Target Price

87.5

P/E

Forward P/E

44.67

PEG

P/S

9.05

P/B

9.89

P/Free Cash Flow

EPS

-2.01

Average EPS Est. Cur. Y

-1.41

EPS Next Y. (Est.)

1.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-22.17

Relative Volume

1.31

Return on Equity vs Sector %

-51.3

Return on Equity vs Industry %

-36.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Tarsus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 323

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today

news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance

stock history TARS – Tarsus Pharmaceuticals Inc invest stock market

stock prices TARS premarket after hours

ticker TARS fair value insiders trading

SPRO – Spero Therapeutics, Inc.

Float Short %

2.58

Margin Of Safety %

Put/Call OI Ratio

0.15

EPS Next Q Diff

EPS Last/This Y

1.17

EPS This/Next Y

0.77

Price

2.6

Target Price

Analyst Recom

Performance Q

20.37

Relative Volume

0.51

Beta

1.45

Ticker: SPRO

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	SPRO	2.32	0.09	0.00	9821
2025-12-10	SPRO	2.34	0.09	0.00	9827
2025-12-11	SPRO	2.36	0.09	0.00	9972
2025-12-12	SPRO	2.32	0.09	0.00	10004
2025-12-15	SPRO	2.3	0.09	0.00	10060
2025-12-16	SPRO	2.29	0.09	0.00	10171
2025-12-17	SPRO	2.32	0.09	0.00	10231
2025-12-18	SPRO	2.31	0.08	0.03	10565
2025-12-19	SPRO	2.34	0.08	0.00	10572
2025-12-22	SPRO	2.37	0.08	0.01	9650
2025-12-23	SPRO	2.33	0.08	0.09	9897
2025-12-26	SPRO	2.32	0.08	0.38	10269
2025-12-29	SPRO	2.29	0.08	3.98	10162
2025-12-30	SPRO	2.29	0.14	0.00	10880
2025-12-31	SPRO	2.33	0.14	0.02	10910
2026-01-02	SPRO	2.35	0.14	0.05	10931
2026-01-05	SPRO	2.43	0.14	1.59	11488
2026-01-06	SPRO	2.51	0.15	0.82	11500
2026-01-07	SPRO	2.61	0.15	0.15	11517
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	SPRO	2.33	-	-	-0.65
2025-12-10	SPRO	2.34	-	-	-0.65
2025-12-11	SPRO	2.35	-	-	-0.65
2025-12-12	SPRO	2.33	-	-	-0.13
2025-12-15	SPRO	2.29	-	-	-0.13
2025-12-16	SPRO	2.29	-	-	-0.13
2025-12-17	SPRO	2.32	-	-	-0.13
2025-12-18	SPRO	2.30	-	-	-0.13
2025-12-19	SPRO	2.34	-	-	-0.10
2025-12-22	SPRO	2.36	-	-	-0.10
2025-12-23	SPRO	2.34	-	-	-0.10
2025-12-26	SPRO	2.32	-	-	-0.10
2025-12-29	SPRO	2.29	-	-	-0.10
2025-12-30	SPRO	2.28	-	-	-0.10
2025-12-31	SPRO	2.33	-	-	-0.10
2026-01-02	SPRO	2.35	-	-	-0.10
2026-01-05	SPRO	2.43	-	-	-0.10
2026-01-06	SPRO	2.51	-	-	-0.10
2026-01-07	SPRO	2.60	-	-	-0.10
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	SPRO	-0.31	0.25	1.51
2025-12-10	SPRO	-0.31	0.25	2.02
2025-12-11	SPRO	-0.31	0.25	2.02
2025-12-12	SPRO	-0.31	0.25	2.02
2025-12-15	SPRO	-0.31	0.25	2.02
2025-12-16	SPRO	-0.31	0.25	2.02
2025-12-17	SPRO	-0.31	0.25	2.02
2025-12-18	SPRO	-0.31	0.25	2.02
2025-12-19	SPRO	-0.31	0.25	2.02
2025-12-22	SPRO	-0.31	0.26	2.02
2025-12-23	SPRO	-0.31	0.26	2.02
2025-12-26	SPRO	-0.31	0.26	2.58
2025-12-29	SPRO	-0.31	0.26	2.58
2025-12-30	SPRO	-0.31	0.26	2.58
2025-12-31	SPRO	-0.31	0.26	2.58
2026-01-02	SPRO	-0.31	0.26	2.58
2026-01-05	SPRO	-0.31	0.26	2.58
2026-01-06	SPRO	-0.31	0.26	2.58
2026-01-07	SPRO	-0.31	0.26	2.58
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

Insider Transactions

-0.31

Institutional Transactions

0.26

Beta

1.45

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.3

Max Drawdown 5-Year %

-97.4

Target Price

P/E

Forward P/E

3.88

PEG

P/S

P/B

5.53

P/Free Cash Flow

EPS

-0.79

Average EPS Est. Cur. Y

-0.1

EPS Next Y. (Est.)

0.67

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-149.52

Relative Volume

0.51

Return on Equity vs Sector %

-192.5

Return on Equity vs Industry %

-177.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.29

EBIT Estimation

Spero Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 32

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today

news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance

stock history SPRO – Spero Therapeutics, Inc. invest stock market

stock prices SPRO premarket after hours

ticker SPRO fair value insiders trading

SLNO – Soleno Therapeutics Inc

Float Short %

18.78

Margin Of Safety %

Put/Call OI Ratio

0.64

EPS Next Q Diff

0.21

EPS Last/This Y

4.57

EPS This/Next Y

3.93

Price

44.37

Target Price

113.54

Analyst Recom

1.08

Performance Q

-28.53

Relative Volume

1.18

Beta

-3.15

Ticker: SLNO

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	SLNO	49.98	0.67	0.14	62957
2025-12-10	SLNO	49.99	0.67	0.14	63097
2025-12-11	SLNO	49.47	0.67	0.67	63093
2025-12-12	SLNO	52.28	0.67	0.05	62603
2025-12-15	SLNO	49.94	0.67	0.64	62683
2025-12-16	SLNO	49.52	0.67	0.02	62794
2025-12-17	SLNO	49.01	0.66	2.37	61147
2025-12-18	SLNO	48.13	0.62	8.17	59479
2025-12-19	SLNO	47.75	0.61	0.32	59109
2025-12-22	SLNO	49.34	0.59	0.15	44441
2025-12-23	SLNO	48.82	0.58	0.04	44625
2025-12-26	SLNO	47.63	0.57	0.52	44106
2025-12-29	SLNO	47.55	0.56	0.34	44151
2025-12-30	SLNO	46.26	0.56	0.08	44487
2025-12-31	SLNO	46.27	0.57	0.06	44450
2026-01-02	SLNO	47.18	0.55	0.06	44605
2026-01-05	SLNO	45.4	0.54	6.70	44778
2026-01-06	SLNO	46.17	0.61	3.54	47052
2026-01-07	SLNO	44.36	0.64	1.31	48150
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	SLNO	50.01	-	-	0.18
2025-12-10	SLNO	50.01	-	-	0.18
2025-12-11	SLNO	49.49	-	-	0.18
2025-12-12	SLNO	51.97	-	-	0.18
2025-12-15	SLNO	49.95	-	-	0.18
2025-12-16	SLNO	49.95	-	-	0.18
2025-12-17	SLNO	49.26	-	-	0.18
2025-12-18	SLNO	48.32	-	-	0.19
2025-12-19	SLNO	47.80	-	-	0.19
2025-12-22	SLNO	49.33	-	-	0.19
2025-12-23	SLNO	48.74	-	-	0.19
2025-12-26	SLNO	47.63	-	-	0.19
2025-12-29	SLNO	47.56	-	-	0.19
2025-12-30	SLNO	46.28	-	-	0.19
2025-12-31	SLNO	46.28	-	-	0.19
2026-01-02	SLNO	47.20	-	-	0.19
2026-01-05	SLNO	45.23	-	-	0.19
2026-01-06	SLNO	46.15	-	-	0.19
2026-01-07	SLNO	44.37	-	-	0.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	SLNO	-0.09	19.10	19.74
2025-12-10	SLNO	-0.09	19.10	18.45
2025-12-11	SLNO	-0.09	19.10	18.45
2025-12-12	SLNO	-0.09	19.10	18.45
2025-12-15	SLNO	-0.09	19.11	18.46
2025-12-16	SLNO	-0.09	19.11	18.46
2025-12-17	SLNO	-0.09	19.11	18.46
2025-12-18	SLNO	-0.09	19.11	18.46
2025-12-19	SLNO	-0.09	19.11	18.46
2025-12-22	SLNO	-0.09	19.08	18.46
2025-12-23	SLNO	-0.09	19.08	18.46
2025-12-26	SLNO	-0.09	19.08	18.78
2025-12-29	SLNO	-0.09	19.10	18.78
2025-12-30	SLNO	-0.09	19.10	18.78
2025-12-31	SLNO	-0.09	19.10	18.78
2026-01-02	SLNO	-0.09	19.10	18.78
2026-01-05	SLNO	0.00	19.54	18.78
2026-01-06	SLNO	0.00	19.54	18.78
2026-01-07	SLNO	0.00	19.54	18.78
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.47

Avg. EPS Est. Current Quarter

0.62

Avg. EPS Est. Next Quarter

0.68

Insider Transactions

Institutional Transactions

19.54

Beta

-3.15

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

50.9

Max Drawdown 5-Year %

-98.2

Target Price

113.54

P/E

Forward P/E

10.79

PEG

P/S

24.16

P/B

4.82

P/Free Cash Flow

EPS

-1.84

Average EPS Est. Cur. Y

0.19

EPS Next Y. (Est.)

4.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-79.5

Relative Volume

1.18

Return on Equity vs Sector %

-42.9

Return on Equity vs Industry %

-27.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

Soleno Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 152

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

stock quote shares SLNO – Soleno Therapeutics Inc Stock Price stock today

news today SLNO – Soleno Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch SLNO – Soleno Therapeutics Inc yahoo finance google finance

stock history SLNO – Soleno Therapeutics Inc invest stock market

stock prices SLNO premarket after hours

ticker SLNO fair value insiders trading

SEEL – Seelos Therapeutics Inc

Float Short %

46.13

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

989.44

EPS This/Next Y

Price

0.39

Target Price

Analyst Recom

Performance Q

-85.02

Relative Volume

Beta

1.87

Ticker: SEEL

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	SEEL	0.39	N/A	N/A	0
2025-12-10	SEEL	0.39	N/A	N/A	0
2025-12-11	SEEL	0.39	N/A	N/A	0
2025-12-12	SEEL	0.39	N/A	N/A	0
2025-12-15	SEEL	0.39	N/A	N/A	0
2025-12-16	SEEL	0.39	N/A	N/A	0
2025-12-17	SEEL	0.39	N/A	N/A	0
2025-12-18	SEEL	0.39	N/A	N/A	0
2025-12-19	SEEL	0.39	N/A	N/A	0
2025-12-22	SEEL	0.39	N/A	N/A	0
2025-12-23	SEEL	0.39	N/A	N/A	0
2025-12-26	SEEL	0.39	N/A	N/A	0
2025-12-29	SEEL	0.39	N/A	N/A	0
2025-12-30	SEEL	0.39	N/A	N/A	0
2025-12-31	SEEL	0.39	N/A	N/A	0
2026-01-02	SEEL	0.39	N/A	N/A	0
2026-01-05	SEEL	0.39	N/A	N/A	0
2026-01-06	SEEL	0.39	N/A	N/A	0
2026-01-07	SEEL	0.39	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-1.48

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

1.87

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

100

Max Drawdown 5-Year %

-100

Target Price

P/E

Forward P/E

PEG

P/S

0.37

P/B

P/Free Cash Flow

EPS

351.04

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

-33.1

Return on Equity vs Industry %

-20.9

EPS 1 7Days Diff

4.1

EPS 1 30Days Diff

4.09

EBIT Estimation

Seelos Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 8

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

stock quote shares SEEL – Seelos Therapeutics Inc Stock Price stock today

news today SEEL – Seelos Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch SEEL – Seelos Therapeutics Inc yahoo finance google finance

stock history SEEL – Seelos Therapeutics Inc invest stock market

stock prices SEEL premarket after hours

ticker SEEL fair value insiders trading

No more stocks to show

XTLB – X.T.L. Biopharmaceuticals Ltd. ADR

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: XTLB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

XNCR – Xencor Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: XNCR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y